All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C20H26N2O · HCl
CAS Number:
Molecular Weight:
346.89
EC Number:
MDL number:
UNSPSC Code:
12352200
drug control
USDEA Schedule I; regulated under CDSA - not available from Sigma-Aldrich Canada
solubility
H2O: soluble
methanol: soluble
application(s)
forensics and toxicology
SMILES string
Cl.CCC1CC2CC3C1N(CCc4c3[nH]c5ccc(OC)cc45)C2
Looking for similar products? Visit Product Comparison Guide
Biochem/physiol Actions
Ibogaine is a central nervous system stimulant and hallucinogen that has been reported to be a σ2 agonist, a noncompetitive NMDA receptor antagonist at the phencyclidine site and an enhancer of purinergic muscle contractions. It is also a competitive inhibitor of serotonin and dopamine transport. It is an anti-convulsant and has anti-addictive properties against cocaine and heroin.
Preparation Note
Alkaloid isolated from the African shrub, Tabernanthe iboga.
Signal Word
Warning
Hazard Statements
Hazard Classifications
Acute Tox. 4 Oral
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
M K Mundey et al.
British journal of pharmacology, 129(8), 1561-1568 (2000-04-26)
Ibogaine and 18-methoxycoronaridine are naturally occurring alkaloids reported to possess antiaddictive properties in several models of drug dependence. We have examined their effect at mu-opioid receptors regulating neurogenic contractions of several smooth muscle preparations and also against spontaneous contractions of
M B Leal et al.
Neurochemical research, 25(8), 1083-1087 (2000-10-31)
Ibogaine, a putative antiaddictive drug, is remarkable in its apparent ability to downgrade withdrawal symptoms and drug craving for extended periods of time after a single dose. Ibogaine acts as a non-competitive NMDA receptor antagonist, while NMDA has been implicated
G B Wells et al.
Brain research bulletin, 48(6), 641-647 (1999-07-01)
Ibogaine has been shown to affect biogenic amine levels in selected brain regions. Because of the involvement of these neurotransmitters in drug addiction, the effects of ibogaine on biogenic amine transport may contribute to the potential anti-addictive properties of ibogaine
K K Szumlinski et al.
Pharmacology, biochemistry, and behavior, 63(3), 457-464 (1999-07-27)
Pretreatment (19 h) with the putative antiaddictive agent, ibogaine, has been shown previously to potentiate cocaine-induced locomotion in rats. The present study demonstrates that the magnitude of this effect of ibogaine is dependent on the previous cocaine history of the
B J Vilner et al.
The Journal of pharmacology and experimental therapeutics, 292(3), 900-911 (2000-02-25)
Human SK-N-SH neuroblastoma cells expressed sigma-1 and sigma-2 receptors with similar pharmacological profiles to those of rodent-derived tissues, although sigma-2 receptors exhibited some affinity differences that might suggest heterogeneity or species differences. Structurally diverse sigma ligands produced two types of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service